Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.
Department of Urology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy.
Minerva Urol Nephrol. 2023 Aug;75(4):425-433. doi: 10.23736/S2724-6051.23.05123-6.
Utility of partial nephrectomy (PN) for complex renal mass (CRM) is controversial. We determined the impact of surgical modality on postoperative renal functional outcomes for CRM.
We retrospectively analyzed a multicenter registry (ROSULA). CRM was defined as RENAL Score 10-12. The cohort was divided into PN and radical nephrectomy (RN) for analyses. Primary outcome was development of de-novo estimated glomerular filtration rate (eGFR)<45 mL/min/1.73 m. Secondary outcomes were de-novo eGFR<60 and ΔeGFR between diagnosis and last follow-up. Cox proportional hazards was used to elucidate predictors for de-novo eGFR<60 and <45. Linear regression was utilized to analyze ΔeGFR. Kaplan-Meier Analysis (KMA) was performed to analyze 5-year freedom from de-novo eGFR<60 and <45.
We analyzed 969 patients (RN=429/PN=540; median follow-up 24.0 months). RN patients had lower BMI (P<0.001) and larger tumor size (P<0.001). Overall postoperative complication rate was higher for PN (P<0.001), but there was no difference in major complications (Clavien III-IV; P=0.702). MVA demonstrated age (HR=1.05, P<0.001), tumor-size (HR=1.05, P=0.046), RN (HR=2.57, P<0.001), and BMI (HR=1.04, P=0.001) to be associated with risk for de-novo eGFR<60 mL/min/1.73 m. Age (HR=1.03, P<0.001), BMI (HR=1.06, P<0.001), baseline eGFR (HR=0.99, P=0.002), tumor size (HR=1.07, P=0.007) and RN (HR=2.39, P<0.001) were risk factors for de-novo eGFR<45 mL/min/1.73 m. RN (B=-10.89, P<0.001) was associated with greater ΔeGFR. KMA revealed worse 5-year freedom from de-novo eGFR<60 (71% vs. 33%, P<0.001) and de-novo eGFR<45 (79% vs. 65%, P<0.001) for RN.
PN provides functional benefit in selected patients with CRM without significant increase in major complications compared to RN, and should be considered when technically feasible.
部分肾切除术 (PN) 治疗复杂肾肿瘤 (CRM) 的效用存在争议。我们旨在确定手术方式对 CRM 术后肾功能结果的影响。
我们回顾性分析了一个多中心登记处 (ROSULA)。CRM 的定义为 RENAL 评分 10-12。该队列分为 PN 和根治性肾切除术 (RN) 进行分析。主要结局是新出现的估计肾小球滤过率 (eGFR)<45 mL/min/1.73 m。次要结局是新出现的 eGFR<60 和诊断与最后一次随访之间的 eGFR 变化。Cox 比例风险用于阐明新出现的 eGFR<60 和 <45 的预测因素。线性回归用于分析 eGFR 变化。Kaplan-Meier 分析 (KMA) 用于分析新出现的 eGFR<60 和 <45 的 5 年无复发率。
我们分析了 969 名患者 (RN=429/PN=540;中位随访 24.0 个月)。RN 患者的 BMI 较低 (P<0.001),肿瘤较大 (P<0.001)。PN 的术后总体并发症发生率较高 (P<0.001),但主要并发症 (Clavien III-IV;P=0.702) 无差异。MVA 显示年龄 (HR=1.05,P<0.001)、肿瘤大小 (HR=1.05,P=0.046)、RN (HR=2.57,P<0.001) 和 BMI (HR=1.04,P=0.001) 与新出现的 eGFR<60 mL/min/1.73 m 的风险相关。年龄 (HR=1.03,P<0.001)、BMI (HR=1.06,P<0.001)、基线 eGFR (HR=0.99,P=0.002)、肿瘤大小 (HR=1.07,P=0.007) 和 RN (HR=2.39,P<0.001) 是新出现的 eGFR<45 mL/min/1.73 m 的危险因素。RN (B=-10.89,P<0.001) 与更大的 eGFR 变化相关。KMA 显示 RN 的新出现的 eGFR<60 (71% vs. 33%,P<0.001) 和 eGFR<45 (79% vs. 65%,P<0.001) 的 5 年无复发率较差。
与 RN 相比,PN 为 CRM 患者提供了功能获益,且不会显著增加主要并发症,在技术可行时应考虑采用。